Supplementary Materials

Supplementary Material for:

Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia

Lishuang Cao, Aoibhinn McDonnell, Anja Nitzsche, Aristos Alexandrou, Pierre-Philippe Saintot, Alexandre J.C. Loucif, Adam R. Brown, Gareth Young, Malgorzata Mis, Andrew Randall, Stephen G. Waxman, Philip Stanley, Simon Kirby, Sanela Tarabar, Alex Gutteridge, Richard Butt, Ruth M. McKernan, Paul Whiting, Zahid Ali, James Bilsland,* Edward B. Stevens*

*Corresponding author. E-mail: j.bilsland{at}ucl.ac.uk (J.B.); edward.stevens{at}pfizer.com (E.B.S.)

Published 20 April 2016, Sci. Transl. Med. 8, 335ra56 (2016)
DOI: 10.1126/scitranslmed.aad7653

This PDF file includes:

  • Fig. S1. Molecular karyotype of IEM and non-IEM iPSCs and Nav channel subtype mRNA expression in iPSC-SNs.
  • Fig. S2. Molecular structure and selectivity profiles of Nav1.7 channel blockers.
  • Fig. S3. Electrophysiological properties of IEM and non-IEM iPSC sensory neurons.
  • Fig. S4. Effect of PF-05153462 on heat sensitivity of non-IEM control D3 and D4 iPSC sensory neurons.
  • Fig. S5. Pharmacokinetic profile of PF-05089771 over time after single oral dose administration to subjects with IEM.
  • Table S1. Common adverse event profile for all five subjects with IEM.

[Download PDF]